Evidence map›Paper›PMID 34585664›Full record

ArticleeLife2021

3'HS1 CTCF binding site in human β-globin locus regulates fetal hemoglobin expression.

Pamela Himadewi, Xue Qing David Wang, Fan Feng, Haley Gore, Yushuai Liu, Lei Yu, Ryo Kurita, Yukio Nakamura, Gerd P Pfeifer, Jie Liu and 1 more

Open access · goldAbstract read
In one paragraph

Article in eLife, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. New Gene Therapy Strategy for β-Thalassemia.Stem cell reviews and reports · 2026
    Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Pamela Himadewi *Center for Epigenetics, Van Andel Research Institute, Grand Rapids, United States.
Xue Qing David Wang *Center for Epigenetics, Van Andel Research Institute, Grand Rapids, United States.
Fan Feng *Department of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, United States.
Haley GoreCenter for Epigenetics, Van Andel Research Institute, Grand Rapids, United States.
Yushuai LiuCenter for Epigenetics, Van Andel Research Institute, Grand Rapids, United States.
Lei YuCell and Development Biology, University of Michigan, Ann Arbor, United States.
Ryo KuritaDepartment of Research and Development, Central Blood Institute, Japanese Red Cross Society, Tokyo, Japan.
Yukio NakamuraCell Engineering Division, RIKEN BioResource Research Center, Tsukuba, Japan.
Gerd P PfeiferCenter for Epigenetics, Van Andel Research Institute, Grand Rapids, United States.ORCID 0000-0002-5080-9604
Jie LiuDepartment of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, United States.ORCID 0000-0002-9504-0587
Xiaotian ZhangCenter for Epigenetics, Van Andel Research Institute, Grand Rapids, United States.ORCID 0000-0002-9533-4761
Van Andel Institute · USUniversity of Michigan · USJapanese Red Cross Society, Japan · JPUniversity of Tsukuba · JP

Funding

Joint analysis of 3D chromatin organization and 1D epigenomeR35HG011279 · NHGRI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LIU, JIE · 2020 to 2024
$2.1M
NHGRI NIH HHS R35 HG011279
6 · The paper itself

Abstract

Mutations in the adult β-globin gene can lead to a variety of hemoglobinopathies, including sickle cell disease and β-thalassemia. An increase in fetal hemoglobin expression throughout adulthood, a condition named hereditary persistence of fetal hemoglobin (HPFH), has been found to ameliorate hemoglobinopathies. Deletional HPFH occurs through the excision of a significant portion of the 3' end of the β-globin locus, including a CTCF binding site termed 3'HS1. Here, we show that the deletion of this CTCF site alone induces fetal hemoglobin expression in both adult CD34+ hematopoietic stem and progenitor cells and HUDEP-2 erythroid progenitor cells. This induction is driven by the ectopic access of a previously postulated distal enhancer located in the

Indexed as

Gene Expression Regulationbeta-GlobinsBinding SitesCCCTC-Binding FactorFetal HemoglobinHematopoietic Stem CellsHemoglobinopathiesHumansMutationProtein BindingReceptors, Odorantbeta-GlobinsCCCTC-Binding FactorCTCF protein, humanFetal HemoglobinOR52A1 protein, humanReceptors, Odorant3D genomicschromosomesepigeneticsgene expressiongeneticsgenomicshemoglobin switchhuman

Identifiers

PMID34585664
PMCPMC8500713
OpenAlexW3204441824

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.